詹楚生醫生 - 血液及血液腫瘤科
血液及血液腫瘤科專科醫生
重點資料
- 醫務委員會註冊已驗證
- 2 個診所地點渣甸山 · 薄扶林
- 血液及血液腫瘤科專科醫生香港中文大學內外全科醫學士 · 香港大學醫學博士 · 香港大學哲學博士 · 1986 年醫科畢業
- 保險計劃資料整理中｜查看詳情
關於醫生
詹楚生醫生是渣甸山及薄扶林的血液及血液腫瘤科醫生。
學歷
血液及血液腫瘤科專科醫生
- 香港中文大學內外全科醫學士1986
- 香港大學醫學博士
- 香港大學哲學博士
- 英國皇家內科醫學院院士
地點
保險計劃
常見問題
詹楚生醫生好嗎？
詹楚生醫生是渣甸山及薄扶林的血液及血液腫瘤科醫生。資歷及註冊資料來自香港醫務委員會。ok.med 不評分，也不排名。
詹楚生醫生是做什麼的？
詹楚生醫生是血液及血液腫瘤科醫生。
詹楚生醫生在哪裡看診？
詹楚生醫生於香港養和醫院、薄扶林應診。
研究及論文
共 61 篇，顯示最近 12 篇
按論文主題篩選
主題由同一批 PubMed 論文的醫學分類整理，不代表醫生提供相關診治服務。
- Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.Clinical hematology international · 2026
- Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.Annals of hematology · 2025
- Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.Clinical hematology international · 2025
- Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.Annals of hematology · 2025
- Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).Blood cancer journal · 2025
- Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM.Bone marrow transplantation · 2024
- Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.Annals of hematology · 2024
- Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.Clinical lymphoma, myeloma & leukemia · 2023
- The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.Therapeutic advances in hematology · 2022
- Epigenetic Silencing of Tumor Suppressor lncRNA <i>NKILA</i>: Implication on NF-κB Signaling in Non-Hodgkin's Lymphoma.Genes · 2022
- miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration.Cell communication and signaling : CCS · 2021
- Case series: MRD negativity assessment using <sup>11</sup>C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma.Therapeutic advances in hematology · 2021
論文資料來自 PubMed／Europe PMC，按姓名及機構自動配對；每項均可按連結核對。
網上資料
以上連結按醫生姓名自動配對，未經醫生本人確認。香港同名者不少，請按連結自行核對。
僅供參考，不構成醫療建議。 閱讀完整免責聲明